Skyline Diagnostics establishes Research Collaboration with Janssen
Skyline Diagnostics B.V. announced that it has signed a Research Agreement with Johnson & Johnson Pharmaceutical Research and Development division of Janssen Pharmaceutica N.V. (Janssen). Under the agreement Skyline, using its proprietary knowledge and technologies in the area of genetic profiling and bioinformatics will work with Janssen to generate and analyze diagnostic information related to the use of an undisclosed, marketed compound. Under the terms of the agreement, Skyline will receive R&D funding and could receive payments on the achievement of certain research milestones. Financial details of the agreement were not disclosed.
"We are very pleased with extension of this exciting companion diagnostic program" said Henk Viëtor, CEO of Skyline Diagnostics, "this collaboration will provide both companies the opportunity to develop a unique personalized medicine approach to help identify patients at increased risk of side effects".
Other news from the department business & finance
